Quantcast

Latest Sarcoma Stories

2009-08-11 07:42:09

A new analysis suggests patients and physicians should rethink the pros and cons of limb-sparing surgery versus amputation for bone and soft tissue sarcomas of the lower limb. Patients with tumors of the bone or soft tissue in their arms and legs require surgery to remove their cancer. To compare the costs and benefits of amputation compared with limb-sparing surgery in these patients, Canadian researchers Ronald Barr, M.D., M.B., Ch.B., of McMaster University and Jay Wunder, M.D., M.Sc., of...

2009-08-10 10:26:59

Limb-sparing surgery, which has been taking the place of amputation for bone and soft tissue sarcomas of the lower limb in recent years, may not provide much or even any additional benefit to patients according to a new review. The analysis, published in the September 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, indicates that patients and physicians should rethink the pros and cons of limb-sparing surgery and amputation.Patients with tumors of the bone or...

2009-06-22 10:10:39

The largest analysis of its kind has found that Caucasians are much more likely than people in other racial/ethnic groups to develop a rare bone and soft tissue cancer called Ewing's sarcoma. In addition, among Caucasians with this cancer, men are more likely to die than women. Published in the August 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that examining the gender and racial differences related to Ewing's sarcoma could provide a...

2009-06-18 10:54:01

A grant from the Liddy Shriver Sarcoma Initiative will allow Dr. Pulivarthi Rao, associate professor of pediatrics at Baylor College of Medicine, and his team of researchers to explore the role of the gene CDC5L in the development of osteosarcoma, the most common bone cancer in children. Rao received the $50,000 one-year grant for his research proposal, "Molecular basis of genomic instability in osteosarcoma." "Osteosarcoma is often present with complex chromosomal rearrangements, deletions...

2009-05-18 12:17:00

SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial...

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been...

2009-04-29 07:55:00

NEW YORK, April 29 /PRNewswire-USNewswire/ -- Blood fluoride levels were significantly higher in patients with osteosarcoma than in control groups, according to research published in Biological Trace Element Research (April 2009). Osteosarcoma, a rare bone cancer, occurs mostly in children and young adults. Randhu and colleagues measured serum fluoride levels in three equal groups of age-matched and sex-matched patients. Group one had osteosarcoma, group two had non-osteosarcoma bone...

2009-03-09 10:26:00

First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the European Commission has formally granted a Centralized marketing authorization for MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The Centralized marketing authorization...

2009-02-26 07:00:00

IRVINE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it is joining the National Organization for Rare Disorders (NORD) and more than 100 patient organizations, caregivers, researchers and companies developing treatments for rare diseases to observe Rare Disease Day on February 28. The goal of the day is to bring attention to rare diseases, the challenges encountered by those affected and the importance of research to develop diagnostics...

2009-02-24 23:01:00

NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas. One of the patients is an 18-year-old with malignant fibrous histiocytoma (MFH) that arose in the largest bone of his leg. The cancer spread throughout his...


Latest Sarcoma Reference Libraries

0_336928514f8c16d00d00e956be85245d
2011-02-17 15:06:48

Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...

More Articles (1 articles) »
Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related